Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761719 | 0.81 | CHRNA7 (0.58) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL1761403 | 0.80 | CHRNA7 (0.56) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL1761414 | 0.80 | P2RX7 (0.55) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL1761660 | 0.80 | GRM5 (0.53) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL1761420 | 0.79 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL1761562 | 0.78 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL1761531 | 0.77 | CHRNA7 (0.52) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL1761695 | 0.77 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL1761888 | 0.76 | CHRNA7 (0.52) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL1761736 | 0.74 | MAPT (0.57) | ADRA2AADRA2BADRA2CHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | claimed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | claimed |
| US-8586746-B2 | Amino-aza-adamantane derivatives and methods of use | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2476681-A2 | Amino-aza-adamantane derivatives and methods of use | Abbott Laboratories (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
| US-7897766-B2 | [3H]-(S,S)-2,2-dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptane, iodide; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, mild cognitive impairment, age-associated memory impairment | ABBOTT LABORATORIES (US) | 2011-03-01 | — | — | US | disclosed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | ADRA2A 61/4885ADRA2B 79/4885ADRA2C 32/4885 |
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | ADRA2A 61/4885ADRA2B 79/4885ADRA2C 32/4885 |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | ADRA2A 61/4885ADRA2B 79/4885ADRA2C 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.